• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肾衰竭患者硝苯地平的血浆浓度。

Plasma concentrations of nifedipine in patients with renal failure.

作者信息

Bogaert M G, Rosseel M T, Joos R, Boelaert J

出版信息

Arzneimittelforschung. 1984;34(3):307-8.

PMID:6539611
Abstract

Plasma concentrations of nifedipine were measured after oral administration of a capsule (Adalat) containing 10 mg of the substance in 6 patients with renal failure not on haemodialysis, in 5 patients with renal failure on haemodialysis and in 6 patients with normal renal function. Whereas the presence of renal failure did not influence the plasma concentrations, lower concentrations were found in the patients on haemodialysis than in the other groups.

摘要

在6例未接受血液透析的肾衰竭患者、5例接受血液透析的肾衰竭患者和6例肾功能正常的患者中,口服含10mg硝苯地平的胶囊(拜新同)后测定血浆硝苯地平浓度。肾衰竭的存在并未影响血浆浓度,但接受血液透析的患者血浆浓度低于其他组。

相似文献

1
Plasma concentrations of nifedipine in patients with renal failure.肾衰竭患者硝苯地平的血浆浓度。
Arzneimittelforschung. 1984;34(3):307-8.
2
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.1α(OH)D3 一α-羟基胆钙化醇——一种活性维生素 D 类似物。关于慢性透析的尿毒症患者继发性甲状旁腺功能亢进症预防和治疗的临床研究。
Dan Med Bull. 2008 Nov;55(4):186-210.
3
Accumulation of vitamin E metabolites in the blood of renal failure patients.维生素E代谢产物在肾衰竭患者血液中的蓄积。
Clin Nutr. 2004 Apr;23(2):205-12. doi: 10.1016/S0261-5614(03)00128-6.
4
Plasma human brain natriuretic peptide in chronic renal failure.慢性肾衰竭患者的血浆人脑钠肽
Clin Nephrol. 1995 Nov;44 Suppl 1:S61-4.
5
Desferrioxamine-induced changes of aluminium kinetics during haemodialysis.
Proc Eur Dial Transplant Assoc. 1981;18:674-80.
6
[Arterial hypertension in patients on chronic hemodialysis].[慢性血液透析患者的动脉高血压]
Srp Arh Celok Lek. 1996 Sep-Oct;124(9-10):246-50.
7
T-cell subset counts and serum immunoglobulin concentrations in patients with chronic renal failure at the Kenyatta National Hospital.
East Afr Med J. 1998 May;75(5):271-3.
8
Growth hormone, IGF-I and its binding proteins (IGFBP-1 and -3) in adult uraemic patients undergoing peritoneal dialysis and haemodialysis.接受腹膜透析和血液透析的成年尿毒症患者的生长激素、胰岛素样生长因子-I及其结合蛋白(IGFBP-1和-3)
Clin Endocrinol (Oxf). 2004 Jun;60(6):741-9. doi: 10.1111/j.1365-2265.2004.02049.x.
9
Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis.去羟肌苷在肾功能正常或慢性肾衰竭的HIV血清阳性患者中的处置:血液透析和持续性非卧床腹膜透析的影响
Clin Pharmacol Ther. 1996 Nov;60(5):535-42. doi: 10.1016/S0009-9236(96)90149-6.
10
Haemodialysis does not affect the pharmacokinetics of nifedipine.血液透析不影响硝苯地平的药代动力学。
Br J Clin Pharmacol. 1985 Aug;20(2):155-8. doi: 10.1111/j.1365-2125.1985.tb05049.x.

引用本文的文献

1
Pharmacodynamics and pharmacokinetics of oral nitrendipine solution in hypertensive patients with advanced renal failure.口服尼群地平溶液在晚期肾衰竭高血压患者中的药效学和药代动力学
Eur J Clin Pharmacol. 1993;45(2):129-34. doi: 10.1007/BF00315493.
2
Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.维拉帕米、硝苯地平和地尔硫䓬的临床药代动力学。
Clin Pharmacokinet. 1986 Nov-Dec;11(6):425-49. doi: 10.2165/00003088-198611060-00002.
3
Pharmacokinetics of nisoldipine in renal dysfunction.尼索地平在肾功能不全患者中的药代动力学。
Eur J Clin Pharmacol. 1988;34(2):207-9. doi: 10.1007/BF00614560.
4
Total and free steady-state plasma levels and pharmacokinetics of nifedipine in patients with terminal renal failure.终末期肾衰竭患者硝苯地平的总稳态血浆水平、游离稳态血浆水平及药代动力学
Eur J Clin Pharmacol. 1989;37(2):185-9. doi: 10.1007/BF00558229.
5
Influence of renal function on the pharmacokinetics and cardiovascular effects of nisoldipine after single and multiple dosing.肾功能对单次及多次给药后尼索地平药代动力学及心血管效应的影响。
Clin Pharmacokinet. 1989 Jan;16(1):55-64. doi: 10.2165/00003088-198916010-00004.
6
Calcium channel antagonists: Part VI: Clinical pharmacokinetics of first and second-generation agents.钙通道拮抗剂:第六部分:第一代和第二代药物的临床药代动力学
Cardiovasc Drugs Ther. 1989 Aug;3(4):482-97. doi: 10.1007/BF01865507.
7
Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.硝苯地平。对其在缺血性心脏病、高血压及相关心血管疾病中的药效学、药代动力学特性及治疗效果的综述。
Drugs. 1985 Sep;30(3):182-274. doi: 10.2165/00003495-198530030-00002.
8
Pharmacokinetics of nifedipine derived from a new retard tablet formulation.新型缓释片剂剂型硝苯地平的药代动力学
Eur J Drug Metab Pharmacokinet. 1990 Oct-Dec;15(4):273-8. doi: 10.1007/BF03190215.
9
Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders.硝苯地平缓释制剂。对其在高血压、缺血性心脏病和周围血管疾病治疗中的当前用途及未来作用的评估。
Drugs. 1991 May;41(5):737-79. doi: 10.2165/00003495-199141050-00006.
10
Clinical pharmacokinetics of calcium antagonists. An update.钙拮抗剂的临床药代动力学。最新进展。
Clin Pharmacokinet. 1992 Jun;22(6):416-33. doi: 10.2165/00003088-199222060-00002.